46.50
+3.45%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oneness Biotech Co
Its shares trade on Taipei Exchange under the ticker 4743.TWO. It has been listed since 19 June 2009. In the fiscal year to 31 December 2025, it reported revenue of TWD 129.1m and a net loss of TWD 1.04bn. At that date it held total assets of TWD 11.73bn and shareholders' equity of TWD 10.33bn.
Oneness Biotech Co., Ltd. engages in the research and development of new drugs, and sale of pharmaceutical products and health products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2009-06-19. The firm's main products include health supplies, health food and healthy food. The firm is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Jun 2009
- Employees
- 12
- Website
- onenessbio.com/tc/index.htm ↗
Leadership
Pay as last reported
- Mr. Hsien-Shou KuoChairman of the Board, since 2010TWD 292,000
- Tingfang ChenFinance Manager
- Ms. Shu-Ling ChengGeneral Manager
- Mr. Yung-Chi ChengDeputy General Manager-Business DepartmentTWD 1.8m
- Ms. Lun-Yin ChouDeputy General Manager-R&D Center ITWD 416,000
- Yiwen SuHead of Corporate Governance
- Aijia YouHead of Accounting
- Mr. Tu-Mu KuoDirector
- Mr. Yi-Fu LinDirectorTWD 33,000
- Ms. Jui-Wen HuangIndependent DirectorTWD 393,000
- Mr. San-Kuei HuangIndependent DirectorTWD 639,000
- Ms. Suei LuIndependent DirectorTWD 396,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 84
- Social
- 99
- Governance
- 79
- Direct emissions (scope 1)
- 183.717 t
- Energy emissions (scope 2)
- 1,530.006 t
- Value chain emissions (scope 3)
- 648.799 t
- Women in the workforce
- 62.4%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oneness Biotech focuses on wound healing treatments for diabetic foot ulcers with new drug development.
- The company develops anticancer drugs alongside health food and health supplies products.
- Oneness Biotech has a small team of 12 employees dedicated to pharmaceutical research and sales.
Weaknesses
- The company operates solely in the domestic market without international expansion.
- Limited employee count of 12 restricts research and development capacity.
- No mention of international distribution channels or global market presence.
Opportunities
- Expanding into new drug development for chronic conditions like diabetic foot ulcers.
- Growing demand for health food and health supplies in the domestic market.
- Potential for new anticancer drug development to address unmet medical needs.
Threats
- Dependence on domestic market limits growth potential and revenue streams.
- Small team size may hinder rapid response to market changes or new opportunities.
- Lack of international presence increases vulnerability to local economic fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.